Latest News
Featured News
Director Dealing
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Select the category
Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+
Share Option Exercise
Scancell initiates new arm (Cohort 4) in SCOPE Phase 2 study to evaluate intradermal administration and an accelerated dosing regimen for iSCIB1+
Director Dealing
Partnership with NHS Cancer Vaccine Launch Pad Enabling Fast-Tracked Access for Melanoma Patients
Scancell to Present Clinical Data from the Ongoing Phase 2 SCOPE Trial of SCIB1 at 2025 AACR Annual Meeting
No results found.
Regulatory News Archive
JOIN OUR MAILING LIST
Sign up for news updates to stay up to date with Scancell.